Los Angeles Capital Management
PETX

Los Angeles Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Los Angeles Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-19,605
Closed -$184K – 1277
2016
Q3 		$184K Buy
+19,605
New +$163K ﹤0.01% 1174
2014
Q2 		– Sell
-20,495
Closed -$380K – 1325
2014
Q1 		$380K Buy
+20,495
New +$411K ﹤0.01% 977

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Los Angeles Capital Management's PETX Position: Q4 2016 in Review

Los Angeles Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2016, closing a stake of 19,605 shares — an estimated $184K sold.

Los Angeles Capital Management first reported a position in PETX in Q1 2014 and held it in 2 quarters. The position peaked at $380K in Q1 2014. 107 funds tracked by Wall St. Rank hold PETX as of Q4 2016.

  • Los Angeles Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Los Angeles Capital Management sold 19,605 Aratana Therapeutics, Inc. shares in Q4 2016, an estimated $184K.
  • Los Angeles Capital Management first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 2 quarters.
  • Los Angeles Capital Management's Aratana Therapeutics, Inc. position peaked at $380K in Q1 2014.
  • 107 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2016.

Based on Los Angeles Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.